在临床实践中,达帕格利弗洛辛在心力衰竭中降低射出分数的预计有效性
Manuel Montero-Pérez-Barquero1, Carlos Escobar-Cervantes2, José Carlos Arévalo-Lorido3
1Internal Medicine, Instituto Maimónides de Investigación Biomédica de Córdoba, University Hospital Reina Sofía, 14004, Córdoba, Spain.
Future cardiology
|June 29, 2023
概括
达帕格利弗洛辛在西班牙实际临床实践中显著降低死亡率和心力衰竭 (HF) 重新入院. 这种SGLT2抑制剂为符合条件的HF患者提供了巨大的好处,改善了生存率并减少了住院治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 减少喷射率 (HFrEF) 的心力衰竭仍然是死亡和住院的重要原因.
- 像达帕格利弗洛辛这样的-葡萄糖共运输体2 (SGLT2) 抑制剂在HFrEF中已经显示出有效性,但现实世界的有效性数据至关重要.
研究的目的:
- 在西班牙临床实践中预测达帕格利弗洛辛在HFrEF患者中的有效性.
- 估计达帕格利弗洛辛对死亡率和心力衰竭再入院的影响.
主要方法:
- 西班牙的一项多中心队列研究包括因心力衰竭住院的患者.
- 预计的益处是使用DAPA-HF试验对符合条件的患者的数据来估计的.
- 分析的重点是医院出院后一年内死亡率和HF再入院率.
主要成果:
- 在1595名注册患者中,有1199名患者有资格接受达帕格利弗洛辛.
- 没有达帕格利弗洛辛,一年后出院率为20.5%的死亡率和21.6%的HF再住院.
- 完全实施达帕格利弗洛辛预计绝对死亡率减少3.5% (NNT=28) 和HF再录取减少6.5% (NNT=15).
结论:
- 在临床实践中使用达帕格利弗洛辛治疗可以显著降低死亡率和心力衰竭再入院.
- 这些发现支持西班牙适用HFrEF患者广泛实施达帕格利弗洛辛.
- 现实数据表明,达帕格利弗洛辛在管理HFrEF和改善患者治疗结果方面发挥了重要作用.
相关概念视频
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:23Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:30Heart Failure IV: Classification and Diagnostic Evaluation
20
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
20
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:26Heart Failure III: Clinical Manifestations
25
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
25